Are your commonly used first-line H. pylori treatments failing you and your patients?
The right H. pylori first-line treatment choice can help you overcome H. pylori resistance and other treatment challenges1,2
High resistance to clarithromycin, as well as to metronidazole and levofloxacin, remains a substantial challenge to H. pylori eradication success1,3
According to the ACG Clinical Guideline1:
Clarithromycin-containing treatment regimens should be avoided without prior resistance testing and demonstrated susceptibility
H. pylori eradication rates with clarithromycin triple regimen2,4*
Lansoprazole triple therapy: 30 mg lansoprazole BID + 1000 mg amoxicillin BID + 500 mg clarithromycin BID for 14 days.
*Data published in 2022 from a large, well-controlled clinical study with clarithromycin triple therapy.
Adherence to H. pylori treatment
Patient adherence to multiprescription therapy can also be a barrier to H. pylori eradication.2,3
- Complex dosing schedules and side effects contribute to poor adherence and treatment failure
- First-line failure reduces chances of success with subsequent treatments
H. pylori eradication
Test and confirm H. pylori eradication: a critical step to help protect your patients from lifelong and potentially life-threatening consequences, including chronic gastritis, peptic ulcer disease, and gastric cancer.1,2
Traditional therapies fail to eradicate H. pylori 25%-40% of the time5-7
References: 1. Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;112(9):1730-1753. 2. Moss SF, Shah SC, Tan MC, El-Serag HB. Evolving concepts in Helicobacter pylori management. Gastroenterology. 2024;166(2):267-283. 3. Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med. 2020;172(12):795-802. 4. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori Infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608-619. 5. Malfertheiner P, Megraud F, O’Morain CA on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. 6. O’Connor A, Gisbert JP, O’Morain C, Ladas S. Treatment of Helicobacter pylori infection 2015. Helicobacter. 2015;20(Suppl 1):54-61. 7. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33-45.